Allogene Therapeutics Announces Participation in February Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in February. Oppenheimer 35th Annual Healthcare Life Sciences ConferenceWednesday, February 1212:20PM PT/3:20PM ET Any available webcasts will be posted to the Company's website at www.a ...